Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy : an early predictor marker of response ?

• Published in: Journal of clinical immunology 1995-07, Vol.15 (4), p.179-184
• Main Authors: PUPPO, F, PICCIOTTO, A, BRENCI, S, VARAGONA, G, SCUDELETTI, M, GHIO, M, BALESTRA, V, CELLE, G, INDIVERI, F
• Format: Article
• Language: English
• Subjects: Adult; Alanine Transaminase - blood; beta 2-Microglobulin - analysis; Biological and medical sciences; Biomarkers - blood; Female; Hepatitis C - immunology; Hepatitis C - therapy; Hepatitis, Chronic - immunology; Hepatitis, Chronic - therapy; Histocompatibility Antigens Class I - blood; HLA Antigens - blood; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - therapeutic use; Male; Medical sciences; Middle Aged; Predictive Value of Tests; Viral diseases; Viral hepatitis
• ISSN: 0271-9142; 1573-2592
• DOI: 10.1007/BF01541087

Soluble HLA class I antigens (sHLA-I), beta 2-microglobulin (beta 2-mu) and alanine aminotransferase (ALT) serum levels have been evaluated in 16 patients affected by chronic hepatitis C treated for six months with recombinant interferon-alpha (rIFN-alpha, 3 MU three times a week). The predictor role of sHLA-I and ALT modifications with respect to the response to rIFN-alpha therapy was also evaluated. Six patients responded (group 1), five patients relapsed followed in initial responses (group 2), and five did not respond to rIFN-alpha treatment (group 3). The baseline serum levels of sHLA-I and beta 2-mu were significantly higher in all three groups of HCV-positive patients with respect to HCV-negative controls (P < 0.05). A significant increase of sHLA-I serum level with respect to baseline value (P < 0.001) was observed in group 1 patients after two weeks of rIFN-alpha treatment. sHLA-I serum level then decreased, although remaining steadily and significantly increased with respect to baseline (P values ranging from 0.05 to 0.01) in the following five months and then returned to baseline one month after the end of rIFN-alpha administration. No significant variations of beta 2-mu serum levels were detected throughout the observation period. In group 1 patients ALT serum levels significantly decreased after two weeks of rIFN-alpha treatment (P < 0.001) and then remained in the normal range throughout the observation period. In the other two groups of patients no relevant variations of sHLA-I and beta 2-mu serum levels were found during and after rIFN-alpha therapy.